BioCentury | Jul 25, 2019
Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

...24 (p=0.02). The company is planning a Phase III trial of the dual NOX1 and NOX4...
...arginase 1; CEP290 - centrosomal protein 290kDa; NOX1 - NADPH oxidase 1; NOX4 - NADPH oxidase 4...
BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

...vs. placebo (p<0.002, p<0.001, respectively). In May, the company reported that the dual NOX1 and NOX4...
...NFE2L2 (NRF2) - Nuclear factor (erythroid-derived 2)-like 2; NOX1 - NADPH oxidase 1; NOX4 - NADPH oxidase 4...
BioCentury | May 2, 2019
Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

...fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI (GSK2834425) Biogen Inc. bluebird bio Inc. Celgene Corp. Genkyotex S.A. GlaxoSmithKline plc Innoviva Inc. Ionis Pharmaceuticals Inc. NADPH oxidase 1 (NOX1) NADPH oxidase 4 (NOX4) Superoxide...
BioCentury | Apr 15, 2019
Distillery Therapeutics

Inhibiting NOX2 or FOXC1 to treat AML and CML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML) Cell culture and mouse studies suggest inhibiting NOX2 or its downstream mediator FOXC1 could help treat AML and CML. In AML cells from...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...metabolism scene, emerging metabolic targets at AACR 2019 include enzymes controlling oxidation. The NADPH oxidase NOX4...
...company, Genkyotex S.A., is inhibiting NOX4 in cancer. The company’s GKT831, a dual NOX1 and NOX4...
...mTORC1 - Mammalian target of rapamycin complex 1 NOX1 - NADPH oxidase 1 NOX4 - NADPH oxidase 4...
BioCentury | Nov 9, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

...Genkyotex hopes to start Phase III testing of the dual NADPH oxidase 1 (NOX1) and NOX4...
...Product: GKT831 Business: Hepatic Molecular target: NADPH oxidase 1 (NOX1); NOX4 Description: Dual NOX1 and NOX4...
...Interim Phase II data Milestone: Additional Phase II data (1H19) Jennie Walters GKT831, gkt137831 Genkyotex S.A. NADPH oxidase 1 (NOX1) NADPH oxidase 4 (NOX4)...
BioCentury | Nov 5, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

...Genkyotex hopes to start Phase III testing of the dual NADPH oxidase 1 (NOX1) and NOX4...
...€0.12 to €1.60 on Monday. Intercept added $0.58 to $110.13. Jennie Walters GKT831, gkt137831 Genkyotex S.A. NADPH oxidase 1 (NOX1) NADPH oxidase 4 (NOX4)...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
BioCentury | Aug 22, 2017
Distillery Therapeutics

Cancer

...INDICATION: Cancer Patient sample and mouse studies suggest inhibiting NOX4 could help treat cancer. In samples...
...of the head and neck (SCCHN), esophageal cancer, colorectal cancer, breast cancer or lung cancer, NOX4...
...and tumor growth compared with normal NOX4 expression or vehicle. Next steps could include testing NOX4...
BioCentury | Aug 8, 2017
Preclinical News

Researchers suggest inhibiting NOX4 could treat cancer

...NADPH oxidase 4 (NOX4) in cancer-associated fibroblasts can abrogate the tumor-promoting function of these cells. The results suggest NOX4...
...myofibroblasts and have been associated with poor survival in cancer patients. The researchers found that NOX4...
...or GKT831 , a dual NOX1 and NOX4 inhibitor from Genkyotex S.A. (Euronext:GKTX), to inhibit NOX4...
Items per page:
1 - 10 of 221